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Abstract
Women with advanced ovarian cancer benefit from the addition of intraperitoneal (IP) chemotherapy after
optimal cytoreductive surgery. Due to catheter complications, many patients are unable to complete IP
chemotherapy. This study looks at a new technique for inserting IP catheters. 38 patients charts were
retrospectively reviewed, two catheter complications were identified: a “flipped” reservoir, and an infection at
the port site. This technique successfully eliminated major catheter complications.
Background: Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. The
NCI released a clinical announcement supporting the use of intraperitoneal chemotherapy in addition to intravenous
chemotherapy. However, multiple trials have shown that IP administration is severely limited by catheter
complications. Purpose: We present a new technique for inserting and securing IP catheters in order to prevent the
previously reported complications, in particular obstruction of the catheter, bowel and vaginal cuff perforation.
Methods: From March 2006 through February 2010, 38 patients with stage III or IV ovarian cancer underwent optimal
cytoreductive surgery and had an IP catheter placed via the “Hammock” technique. Results: 14 patients underwent
modified posterior exenteration (37%); 6 underwent splenectomy (16%); thirteen small bowel resections (34%). All 38
patients underwent pelvic and aortic lymphadenectomy. Two patients had reservoir complications; one “flipped
over”, and the other had an infection at the port site. Both patient’s elected to discontinue the IP portion of the
chemotherapy regimen. 219 cycles of chemotherapy were completed (96%) out of a possible 228 cycles. The only
complications were related to the reservoir. There were no catheter-related complications. Conclusion: As an
increasing number of IP catheters are placed at the time of cytoreductive surgery, we will continue to have catheter
complications and IP chemotherapy administration difficulties. In using the “Hammock” Technique, we had no
catheter complications, and a 96% chemotherapy completion rate. We recommend using the “Hammock” Technique
for inserting and securing IP catheters at the time of cytoreductive surgery. .
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Ovarian cancer is the leading cause of death from gynecologic
malignancies in the United States with 21,550 new cases and 14,600
new deaths estimated in 2009 largely because the majority of patients
present with advanced-stage disease at the time of diagnosis.1 Tradi-
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linical Ovarian & Other Gynecologic Cancer June 2012tionally, advanced ovarian cancer was treated with cytoreductive sur-
gery and intravenous (IV) chemotherapy.2 Now a paradigm shift is
taking place in the management of advanced ovarian cancer. After
completion of multiple large National Cancer Institute (NCI)–spon-
sored randomized clinical trials, all showing improved median sur-
vival associated with the use of intraperitoneal (IP) chemotherapy in
optimally debulked stage III epithelial ovarian cancer, 3-7 the NCI
released a clinical announcement supporting the use of intraperito-
neal chemotherapy in advanced ovarian cancer patients who were
optimally debulked.8
Armstrong et al6 found that 119 of 205 patients (58%) did not
receive six planned cycles of IP chemotherapy. Forty patients
(19.5%) discontinued IP chemotherapy because of catheter-related
complications. Complications associated with IP catheters remain a
legitimate concern, and are a major hurdle to patients completing the
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arecommended six cycles of IP chemotherapy. Reported complication
rates vary from 3% to 34.6%9-17 and include catheter infection,
blockage, and leakage. To a lesser extent, abdominal pain, access
problems, vaginal vault perforation, bladder erosion, and bowel per-
foration have also been reported.9-17
The purpose of this article is to present a new technique for insert-
ing and securing IP catheters to prevent many of the previously
reported complications, in particular, obstruction of the catheter,
and bowel and vaginal cuff perforations.9-17
Technique
At the completion of optimal cytoreductive surgery, a subcutane-
ous pocket is created over the last two ribs on the patients’ right side.
In patients undergoing extensive cytoreduction requiring an incision
from the xyphoid to the symphysis, this pocket can be created as a
direct extension from the midline incision into the subcutaneous
tissues. In those patients with a limited incision, a 3-cm incision can
be made on the patients’ right side overlying the last two ribs. The
subcutaneous tissue is dissected and a pocket is developed at the level
of the fascia. Using a tunneling device, the peritoneum and the fascia
is penetrated approximately 10 cm distal to the reservoir pocket. The
catheter is then attached to the tunneler, withdrawn from the peri-
toneal cavity through the subcutaneous tissues, and connected to the
reservoir. We use a Power Port* Implantable Port with Suture Plugs
with Attachable 8F Groshong Single Lumen Venous Catheter (Bard
Access Systems, Inc, Salt Lake City, UT). We use the largest venous
catheter system available. The reservoir is flushed with heparinized
saline to test for patency. Vicryl 3-0 interrupted sutures are used to
secure the reservoir to the fascia overlying the ribs. We then secure
our catheter along the lateral anterior abdominal wall/sidewall using
our “Hammock” technique. Using 0 vicryl or monocryl suture, the
peritoneum is grasped on either side of the catheter, and an inter-
rupted stitch is thrown. This is performed two or three times to
secure the catheter to the abdominal wall well lateral to the midline
incision (Figure 1). Catheter patency is tested again with heperanized
saline. Care is taken to ensure the catheter is not so long as to inter-
twine with loops of small intestine and is trimmed if necessary. Fas-
Figure 1 The “Hammock” Techniquecial and skin incisions are then closed.Results
From March 2006 through February 2010, 38 patients who
had stage III or IV ovarian cancer after having undergone optimal
cytoreductive surgery (less than 5 mm of residual disease) had an
IP catheter placed as described above. During primary surgery,
Seprafilm (Cambridge, MA) was placed with the intent to mini-
mize adhesion formation. Fourteen patients underwent modified
posterior exenteration (37%); 6 underwent splenectomy (16%);
13 small bowel resections (34%); and all 38 underwent aortic and
pelvic lymphadenectomy. Patients were scheduled to receive six
cycles of IV taxol (AUC 5 or 6) and IP cisplatin 75 mg/m2. Two
atients had reservoir complications that were identified on phys-
cal examination during prechemotherapy visits. One reservoir
flipped over” after the first cycle of chemotherapy, requiring
eplacement, and one patient suffered from an infection at the
ort site after the second cycle resulting in the removal of the
eservoir. In each case the patient elected to discontinue the IP
ortion of their chemotherapy regimen. Two hundred nineteen
96%) cycles of chemotherapy were completed of a possible 228
ycles. The only complications were related to the reservoir, and
here were no catheter-related complications.
Discussion
A paradigm shift is taking place in the management of advanced
ovarian cancer as a result of multiple trials, which show that the
addition of IP chemotherapy to IV chemotherapy improves survival
in advanced ovarian cancer patients after optimal cytoreductive sur-
gery.3-7 However, the planned number of IP chemotherapy courses
is not completed in a significant number of patients because of cath-
eter complications. Walker et al13 reported that 19.5% of patients in
he IP arm of Gynecologic Oncology Group study GOG 172 did not
omplete the number of prescribed courses of IP chemotherapy sec-
ndary to catheter complications such as infection, blockage, leak-
ge, and access problems. Fujiwara et al18 documented that approx-
mately 10% of the patients undergoing IP chemotherapy had
atheter-related complications. Of perhaps more significance, Gad-
ucci et al,19 in a study closed because of inadequate accrual, re-
orted that 20 patients assigned to the IP chemotherapy arm did not
omplete treatment. The catheter was obstructed in 3 patients, and
n 3 others the IP catheter had eroded into the intestine. Others
iscontinued treatment secondary to abdominal pain, peritonitis,
nd a variety of other reasons, none of which reached the significance
f the bowel perforations and catheter blockages, making it clear that
very effort should be made to prevent the catheter from coming into
ontact with the intestine.
No trials comparing available reservoir and catheter systems have
een undertaken. Alberts et al20 suggest that the use of Port-A-Cath
esigned for IV injection should replace Port-A-Cath designed for IP
njection because it appears to prevent fibrous sheath formation and
reatly decreases the risk of small bowel obstruction and perforation.
lack et al9 and Makhija et al10 reported lower complication rates
with the BardPort titanium reservoir with a fenestrated silicone rub-
ber catheter. Landrum et al11 reported lower complication rates with
single lumen, venous silicone catheter. Ivy et al21 reviewed 81
patients who had IP ports placed: 67(83%) at the time of initial
cytoreductive surgery and 14(17%) placed at a secondary time. Fifty-
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26 Ctwo (64%) patients had a fenestrated port placed, and 29 (36%) had
a single lumen port placed. They found no significant difference in
the number of IP treatments received, the number of catheter-related
complications, or the rates of discontinuation.
Other methods of delivering IP chemotherapy have been de-
scribed. Yamaguchi et al22 used real-time transvaginal ultrasound–
guided instillation of IP chemotherapy in 11 patients who had ovar-
ian cancer. The average time of instillation was 23.9 minutes. The
only complication observed was hematuria. Lan et al23 used a periph-
ral venous needle with a catheter (16 ga, 1.7 83 mm) to deliver IP
hemotherapy in 194 patients with ovarian, fallopian tube, and pri-
ary peritoneal cancer. 62.4% of patients were able to complete six
r more cycles of IP chemotherapy (patients with large residual dis-
ase received more than six cycles of IP chemotherapy); 37.6% of
atients did not complete six cycles of IP chemotherapy. Reasons for
essation were categorized as IP-access related, possibly IP-access re-
ated, and not IP-access related. IP-access–related reasons were noted
n 1.0%, possibly IP-access–related reasons in 14.9%, and reasons
ot related to IP access were found in 18.1% of patients, respectively.
A potential weakness of this study is its retrospective nature. How-
ver, since implementing this technique in 2006, we have not noted
ny catheter blockages, vaginal cuff erosions, bowel perforations, or
ladder erosions in our patient population. Furthermore, prospective
tudies are necessary to compare surgical techniques of IP catheter
lacement, differences in reservoir systems, and possibly other ways
f administering IP chemotherapy to advanced ovarian cancer
atients.
Clinical Practice Points
● Current literature has shown that many patients with IP catheters
have complications precluding them from receiving intraperito-
neal chemotherapy.
● This study demonstrates a new technique for IP catheter insertion
for which we experienced no catheter blockages, no vaginal cuff
erosions, bowel perforations or bladders erosions.
● If this technique is regularly used in clinical practice, it has the
potential to decrease the number of catheter complications expe-
rienced by advanced ovarian cancer patients.
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